RT Journal Article
SR Electronic
T1 Characterization of human airway epithelial cell lines as in vitro models of chronic obstructive pulmonary disease
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3701
DO 10.1183/13993003.congress-2021.PA3701
VO 58
IS suppl 65
A1 Aude Bodin
A1 Tatiana Victoni
A1 Yann Verres
A1 Pascale Bellaud
A1 Alain Fautrel
A1 Thomas Gicquel
A1 Françoise Pons
A1 Vincent Lagente
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3701.abstract
AB Airway epithelial cells produce mucus to protect against toxic agents and pathogens. However, when the mucus accumulates can become pathological – a characteristic of chronic obstructive pulmonary disease (COPD). The effectiveness of inhaled drugs is reduced by excess mucus and the effectiveness of gene vectors delivered to the airways is decreased by the presence of a viscous mucus barrier. The objective of the present study was to develop an in vitro model capable of cytokine production and mucus secretion to test new drugs. Then, we stimulated three different human airway epithelial cell lines (A549, Calu-3, and NCI-H292) with various concentrations of cigarette smoke extract (CSE) alone or in association with lipopolysaccharide (LPS). In Calu-3, any stimulation did not affect MUC5AC and cytokine gene expression or protein secretion. In contrast, A549 exposure to CSE and LPS was associated with greater release of IL-8/CXCL8, GRO-α/CXCL1 and MCP-1/CCL2 proteins, but not on mucus production. However, for NCI-H292, CSE alone was associated with elevated mucus production, and an additive effect was observed when CSE was combined with LPS (except for MCP-1/CCL2). Lastly, in the NCI H292 and Calu-3 co-culture, the combination of CSE and LPS was associated with greater MUC5AC gene expression and LPS was associated with greater secretion of only IL-8/CXCL8. Our results indicate that NCI-H292 cells constitute the most appropriate in vitro model for studying inflammatory mediator secretion and mucus production as a guide to the efficacy of new mucolytic drug candidates and gene therapy vectors.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3701.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).